386 related articles for article (PubMed ID: 15604885)
21. A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657.
Sohal J; Phan VT; Chan PV; Davis EM; Patel B; Kelly LM; Abrams TJ; O'Farrell AM; Gilliland DG; Le Beau MM; Kogan SC
Blood; 2003 Apr; 101(8):3188-97. PubMed ID: 12515727
[TBL] [Abstract][Full Text] [Related]
22. FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L).
Bagrintseva K; Geisenhof S; Kern R; Eichenlaub S; Reindl C; Ellwart JW; Hiddemann W; Spiekermann K
Blood; 2005 May; 105(9):3679-85. PubMed ID: 15626738
[TBL] [Abstract][Full Text] [Related]
23. Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML.
Jiang J; Paez JG; Lee JC; Bo R; Stone RM; DeAngelo DJ; Galinsky I; Wolpin BM; Jonasova A; Herman P; Fox EA; Boggon TJ; Eck MJ; Weisberg E; Griffin JD; Gilliland DG; Meyerson M; Sellers WR
Blood; 2004 Sep; 104(6):1855-8. PubMed ID: 15178581
[TBL] [Abstract][Full Text] [Related]
24. [Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].
Müller-Tidow C; Steur C; Mizuki M; Schwäble J; Brandts C; Berdel WE; Serve H
Dtsch Med Wochenschr; 2002 Oct; 127(42):2195-200. PubMed ID: 12397548
[TBL] [Abstract][Full Text] [Related]
25. [Mutations of the gene coding for the receptor tyrosine kinase FLT3 in acute myeloid leukemia. Significance as the disease-specific molecular marker for diagnosis, prognosis and innovative therapy approaches].
Spiekermann K; Hiddemann W; Schnittger S
Dtsch Med Wochenschr; 2005 Apr; 130(16):1020-5. PubMed ID: 15830315
[No Abstract] [Full Text] [Related]
26. FLT3 tyrosine kinase as a target molecule for selective antileukemia therapy.
Naoe T; Kiyoe H; Yamamoto Y; Minami Y; Yamamoto K; Ueda R; Saito H
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S27-30. PubMed ID: 11587362
[TBL] [Abstract][Full Text] [Related]
27. FLT3 inhibitors in acute myeloid leukemia.
el-Shami K; Stone RM; Smith BD
Expert Rev Hematol; 2008 Dec; 1(2):153-60. PubMed ID: 21082920
[TBL] [Abstract][Full Text] [Related]
28. Novel FLT3 tyrosine kinase inhibitors.
Levis M; Small D
Expert Opin Investig Drugs; 2003 Dec; 12(12):1951-62. PubMed ID: 14640939
[TBL] [Abstract][Full Text] [Related]
29. Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia.
Prescott H; Kantarjian H; Cortes J; Ravandi F
Expert Opin Emerg Drugs; 2011 Sep; 16(3):407-23. PubMed ID: 21417961
[TBL] [Abstract][Full Text] [Related]
30. FLT3 in human hematologic malignancies.
Kiyoi H; Naoe T
Leuk Lymphoma; 2002 Aug; 43(8):1541-7. PubMed ID: 12400596
[TBL] [Abstract][Full Text] [Related]
31. RNAi-induced down-regulation of FLT3 expression in AML cell lines increases sensitivity to MLN518.
Walters DK; Stoffregen EP; Heinrich MC; Deininger MW; Druker BJ
Blood; 2005 Apr; 105(7):2952-4. PubMed ID: 15585651
[TBL] [Abstract][Full Text] [Related]
32. Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic/severe combined immunodeficient mice.
Piloto O; Levis M; Huso D; Li Y; Li H; Wang MN; Bassi R; Balderes P; Ludwig DL; Witte L; Zhu Z; Hicklin DJ; Small D
Cancer Res; 2005 Feb; 65(4):1514-22. PubMed ID: 15735040
[TBL] [Abstract][Full Text] [Related]
33. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.
O'Farrell AM; Foran JM; Fiedler W; Serve H; Paquette RL; Cooper MA; Yuen HA; Louie SG; Kim H; Nicholas S; Heinrich MC; Berdel WE; Bello C; Jacobs M; Scigalla P; Manning WC; Kelsey S; Cherrington JM
Clin Cancer Res; 2003 Nov; 9(15):5465-76. PubMed ID: 14654525
[TBL] [Abstract][Full Text] [Related]
34. FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases.
Yao Q; Nishiuchi R; Li Q; Kumar AR; Hudson WA; Kersey JH
Clin Cancer Res; 2003 Oct; 9(12):4483-93. PubMed ID: 14555522
[TBL] [Abstract][Full Text] [Related]
35. A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia.
Spiekermann K; Bagrintseva K; Schoch C; Haferlach T; Hiddemann W; Schnittger S
Blood; 2002 Nov; 100(9):3423-5. PubMed ID: 12384447
[TBL] [Abstract][Full Text] [Related]
36. A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations.
Levis M; Tse KF; Smith BD; Garrett E; Small D
Blood; 2001 Aug; 98(3):885-7. PubMed ID: 11468194
[TBL] [Abstract][Full Text] [Related]
37. FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells.
Zheng R; Levis M; Piloto O; Brown P; Baldwin BR; Gorin NC; Beran M; Zhu Z; Ludwig D; Hicklin D; Witte L; Li Y; Small D
Blood; 2004 Jan; 103(1):267-74. PubMed ID: 12969963
[TBL] [Abstract][Full Text] [Related]
38. FLT3 Inhibitors in the Treatment of AML.
Gilliland DG
Clin Adv Hematol Oncol; 2004 Nov; 2(11):708-10. PubMed ID: 16163256
[No Abstract] [Full Text] [Related]
39. Bis(1H-2-indolyl)-1-methanones as inhibitors of the hematopoietic tyrosine kinase Flt3.
Teller S; Krämer D; Böhmer SA; Tse KF; Small D; Mahboobi S; Wallrapp C; Beckers T; Kratz-Albers K; Schwäble J; Serve H; Böhmer FD
Leukemia; 2002 Aug; 16(8):1528-34. PubMed ID: 12145694
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.
Weisberg E; Boulton C; Kelly LM; Manley P; Fabbro D; Meyer T; Gilliland DG; Griffin JD
Cancer Cell; 2002 Jun; 1(5):433-43. PubMed ID: 12124173
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
